CERSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

CERUS CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$2.22+0.04 (+1.83%)

Close on Oct 19, 2026

Market cap: $445.25M
P/E (TTM): –
Dividend yield: –

CERUS CORP income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31
Revenue	234	201	187	188	160	114	94	76	51	39	34	36	40	37	33	23	18
Cost of Revenue	–	–	–	–	–	41	33	32	23	20	23	21	23	21	19	12	13
Gross Profit	–	–	–	–	–	73	60	44	29	17	11	15	17	16	12	9.63	5.40
Research & Development	68	59	68	64	64	64	60	43	34	31	26	22	15	7.60	7.18	5.20	6.37
Selling, General & Admin	81	76	76	83	81	67	66	57	53	49	46	38	30	26	23	22	22
Operating Expenses	149	135	147	147	145	131	127	99	86	80	72	60	45	33	30	27	29
Operating Income	-8.68	-14	-30	-34	-49	-58	-66	-55	-58	-61	-61	-45	-28	-17	-16	-16	-24
Interest Expense	8.34	8.88	8.39	5.83	4.92	3.75	6.07	4.01	3.02	2.45	1.71	0.60	0.33	0.55	0.96	0.69	0.01
Other Non-Operating Income	-6.60	-6.53	-7.27	-8.26	-5.12	-1.24	-4.76	-2.35	0.83	-1.28	1.54	5.94	-15	1.63	-0.92	-0.86	-0.30
Merger & Restructuring Charges	–	0	3.70	–	–	–	–	–	–	–	–	–	–	–	0	0	0.84
Asset Impairment Charges	0	0	1.70	0	0	0.30	0	0	0	0.15	0	0	0	0	0	0	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	-0.02	-0.01	–	–	–	0.00	-0.06	0	0.11	-0.05	-0.10
Legal Settlements	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	1.38
Pretax Income	-15	-21	-37	-42	-54	-60	-71	-57	-57	-63	-60	-39	-43	-16	-17	-17	–
Income Tax Expense	0.35	0.21	0.33	0.49	0.32	0.28	0.26	0.23	3.89	0.18	-3.67	0.20	0.22	0.24	0.14	0.09	–
Net Income incl. Noncontrolling Interests	-16	-21	-38	-43	-54	-60	-71	-58	-61	-63	–	–	–	–	–	–	–
Minority Interest in Earnings	-0.01	-0.04	-0.16	-0.05	0.00	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-16	-21	-37	-43	-54	-60	-71	-58	-61	-63	-56	-39	-43	-16	-17	-17	-24
Net Income to Common	–	–	–	–	–	–	–	–	-61	-63	-59	-46	-43	-18	-17	-17	–
EPS (Basic)(per share)	-0.08	-0.11	-0.21	-0.24	-0.32	-0.37	-0.51	-0.44	-0.56	-0.62	-0.58	-0.52	-0.64	-0.29	-0.35	-0.42	-0.69
EPS (Diluted)(per share)	-0.08	-0.11	-0.21	-0.24	-0.32	-0.37	-0.51	-0.44	-0.56	-0.62	-0.61	-0.61	-0.64	-0.33	-0.35	-0.42	-0.69
Shares Outstanding (Basic, Weighted)(shares)	191	185	180	177	171	164	140	132	108	102	96	75	68	55	48	40	35
Shares Outstanding (Diluted, Weighted)(shares)	191	185	180	177	171	164	140	132	108	102	97	77	68	55	48	40	35
EBITDA	-7.26	-12	-27	-31	-46	-55	-64	-54	-56	-60	-59	-43	-28	-17	-15	-15	-23

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -0.7%
Net margin: -2.9%
Return on equity, FY2025: -26.0%

Financial strength

Current ratio: 1.83
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 21.0%

Valuation

P/E ratio: –
Price to sales: 1.90
Price to book: 6.36
Dividend yield: –